<DOC>
	<DOCNO>NCT00996268</DOCNO>
	<brief_summary>Sixteen healthy subject randomize 3 parallel treatment group . Eligible subject check clinical unit Day -2 24-hr pharmacokinetic collection Day -1 Day 1 . Once pharmacokinetic parameter formulation analyze , dose GSK2212836 select study Part B . Subjects Part A participate Part B . Part B single blind , randomize , placebo control study consist 2-week repeat dose period 3 dose level one dose market formulation GSK2212836 . Subjects check clinical unit Day -3 ; participate test meal Day -2 24-hr baseline pharmacokinetic profile Day -1 Day 1 . Subjects release clinic Day 2 , return daily dose Days 3 12 . On Day 6 , also brief outpatient visit . Subjects check clinic evening Day 12 , Day 13 24-hr pharmacokinetic profile collect . Subjects release clinical research unit Day 14 , follow test meal , triglyceride sample check-out assessment , release study 5-10 day later complete follow visit .</brief_summary>
	<brief_title>An Open-label Single Dose Randomized , Parallel Group Study Followed Single-blind Repeat Dosing , Compare Relative Bioavailability GSK2212836 .</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>AST , ALT , alkaline phosphatase bilirubin le 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Healthy determine responsible experienced physician , base medical evaluation include [ medical history , physical examination , laboratory test ECGs . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 18 50 year age inclusive , time signing informed consent . A female subject eligible participate Childbearing potential agrees use one contraception method list protocol . Body weight great equal 50kg ( 110 lb ) men great equal 45 kg woman BMI within range 2434kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . Average QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define : The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Use omega3 fatty acid supplement and/or fish fish oil product screen final assessment unwilling abstain eat oily fish ( salmon , albacore tuna , mackerel , sardine , etc . ) course study . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . History sensitivity know allergy fish /or shellfish . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive hCG test screening ( serum ) prior dose ( urine ) . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . Unable abstain smoking tobacco use nicotinecontaining product clinic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>hypertriglyceridemia</keyword>
	<keyword>GSK2212836</keyword>
	<keyword>relative bioavailability</keyword>
</DOC>